Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Dupixent demonstrated superior efficacy in ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

About Dupixent Dupixent, which was invented using Regeneron’s proprietary VelocImmune ® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4 ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results ...